Paolo Marchetti | Ricerc@Sapienza

Pubblicazioni

Titolo	Pubblicato in	Anno
Adjuvant vemurafenib in resected, BRAF V600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial	THE LANCET ONCOLOGY	2018
Observational study of coagulation activation in early breast cancer. development of a prognostic model based on data from the real world setting	JOURNAL OF TRANSLATIONAL MEDICINE	2018
Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab	CANCER BIOLOGY & THERAPY	2018
Systemic chemotherapy for advanced rare pancreatic histotype tumors: A retrospective multicenter analysis	PANCREAS	2018
Sarcopenia is associated with reduced survival in patients with advanced hepatocellular carcinoma undergoing sorafenib treatment	UNITED EUROPEAN GASTROENTEROLOGY JOURNAL	2018
Non-invasive visualization of tumor infiltrating lymphocytes in patients with metastatic melanoma undergoing immune checkpoint inhibitor therapy. A pilot study	ONCOTARGET	2018
Resolution of remitting seronegative symmetrical synovitis with pitting edema (RS3PE) during Nivolumab therapy for non-small cell lung cancer: a case report	SEMINARS IN ARTHRITIS AND RHEUMATISM	2018
Evaluation of 5-fluorouracil degradation rate and pharmacogenetic profiling to predict toxicity following adjuvant capecitabine	EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY	2017
Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment	ONCOTARGET	2017
Angiosarcoma of the breast: a rare and dismal complication of breast surgery associated with radiation	THE AMERICAN SURGEON	2017
Tackling pancreatic cancer with metronomic chemotherapy	CANCER LETTERS	2017
Pharmacogenetic Approach to Toxicity in Breast Cancer Patients Treated with Taxanes	ANTICANCER RESEARCH	2017
A nomogram to predict 5-fluorouracil toxicity: when pharmacogenomics meets the patient	ANTI-CANCER DRUGS	2017
Current achievements and future perspectives of metronomic chemotherapy	INVESTIGATIONAL NEW DRUGS	2017
Patient database analysis of fulvestrant 500 mg in the treatment of metastatic breast cancer: A European perspective	THE BREAST	2017
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience	ONCOTARGET	2017
Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: the EverExt study	SCIENTIFIC REPORTS	2017
PD-L1 expression in TNBC: a predictive biomarker of response to neoadjuvant chemotherapy?	BIOMED RESEARCH INTERNATIONAL	2017
The role of stereotactic body radiation therapy in oligometastatic colorectal cancer	MEDICINE	2017
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients	EUROPEAN JOURNAL OF CANCER	2017